ZA200303214B - O-substituated 6-methyl-tramadol derivatives. - Google Patents

O-substituated 6-methyl-tramadol derivatives. Download PDF

Info

Publication number: ZA200303214B
Authority: ZA; South Africa
Prior art keywords: dimethylaminomethyl; substituted; methyltramadol; methylcyclohexanol; derivatives
Prior art date: 2000-09-29

Application number

ZA200303214A

Other languages

English (en)

Inventor

Helmut Bushmann

Elmar Friderichs

Babette-Yvonne Koegel

Dagmar Kaulartz

Original Assignee

Gruenenthal Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-29

Filing date

2003-04-24

Publication date

2004-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7658871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200303214(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-04-24 Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh

2004-08-31 Publication of ZA200303214B publication Critical patent/ZA200303214B/en

Links

150000003839 salts Chemical class 0.000 claims description 26
208000004454 Hyperalgesia Diseases 0.000 claims description 24
208000002193 Pain Diseases 0.000 claims description 21
150000001875 compounds Chemical class 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 16
DMVJUXLKJXRMSV-UHFFFAOYSA-N 3-[2-[(dimethylamino)methyl]-1-hydroxy-6-methylcyclohexyl]phenol Chemical compound CC1CCCC(CN(C)C)C1(O)C1=CC=CC(O)=C1 DMVJUXLKJXRMSV-UHFFFAOYSA-N 0.000 claims description 15
-1 3-cyclopentyloxyphenyl Chemical group 0.000 claims description 13
239000000203 mixture Substances 0.000 claims description 13
239000002253 acid Substances 0.000 claims description 12
238000000034 method Methods 0.000 claims description 12
239000000126 substance Substances 0.000 claims description 12
230000036407 pain Effects 0.000 claims description 10
239000000470 constituent Substances 0.000 claims description 9
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 8
150000007513 acids Chemical class 0.000 claims description 8
206010053552 allodynia Diseases 0.000 claims description 8
229920006395 saturated elastomer Polymers 0.000 claims description 8
229910052717 sulfur Inorganic materials 0.000 claims description 8
ZDAVLYNMOVBPQN-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-6-methylcyclohexan-1-one Chemical compound CC1CCCC(CN(C)C)C1=O ZDAVLYNMOVBPQN-UHFFFAOYSA-N 0.000 claims description 7
208000000094 Chronic Pain Diseases 0.000 claims description 7
239000002585 base Substances 0.000 claims description 7
230000001684 chronic effect Effects 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
238000011282 treatment Methods 0.000 claims description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
150000004677 hydrates Chemical class 0.000 claims description 6
239000012453 solvate Substances 0.000 claims description 6
125000001544 thienyl group Chemical group 0.000 claims description 6
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
208000004296 neuralgia Diseases 0.000 claims description 5
230000002981 neuropathic effect Effects 0.000 claims description 5
208000021722 neuropathic pain Diseases 0.000 claims description 5
XPMNKWJIZAMUQL-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-6-methylcyclohexan-1-ol Chemical compound COC1=CC=CC(C2(O)C(CCCC2C)CN(C)C)=C1 XPMNKWJIZAMUQL-UHFFFAOYSA-N 0.000 claims description 4
208000035154 Hyperesthesia Diseases 0.000 claims description 4
206010065390 Inflammatory pain Diseases 0.000 claims description 4
208000019695 Migraine disease Diseases 0.000 claims description 4
208000004550 Postoperative Pain Diseases 0.000 claims description 4
208000005298 acute pain Diseases 0.000 claims description 4
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
230000002757 inflammatory effect Effects 0.000 claims description 4
206010027599 migraine Diseases 0.000 claims description 4
239000000654 additive Substances 0.000 claims description 3
150000002902 organometallic compounds Chemical class 0.000 claims description 3
ODIDACTUQHIJOO-UHFFFAOYSA-N 1-(3-cyclobutyloxyphenyl)-2-[(dimethylamino)methyl]-6-methylcyclohexan-1-ol Chemical compound CC1CCCC(CN(C)C)C1(O)C1=CC=CC(OC2CCC2)=C1 ODIDACTUQHIJOO-UHFFFAOYSA-N 0.000 claims description 2
AZFWCGWLDUTDPS-UHFFFAOYSA-N 1-[3-(cyclobutylmethoxy)phenyl]-2-(dimethylamino)-2,6-dimethylcyclohexan-1-ol Chemical compound CC1CCCC(C)(N(C)C)C1(O)C1=CC=CC(OCC2CCC2)=C1 AZFWCGWLDUTDPS-UHFFFAOYSA-N 0.000 claims description 2
WZAOSRXZLLMHJH-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(3-ethoxyphenyl)-6-methylcyclohexan-1-ol Chemical compound CCOC1=CC=CC(C2(O)C(CCCC2C)CN(C)C)=C1 WZAOSRXZLLMHJH-UHFFFAOYSA-N 0.000 claims description 2
QMAFQXOLZSALTJ-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(3-ethynoxyphenyl)-6-methylcyclohexan-1-ol Chemical compound CC1CCCC(CN(C)C)C1(O)C1=CC=CC(OC#C)=C1 QMAFQXOLZSALTJ-UHFFFAOYSA-N 0.000 claims description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 2
239000012458 free base Substances 0.000 claims description 2
159000000000 sodium salts Chemical class 0.000 claims description 2
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
MQWCXKGKQLNYQG-UHFFFAOYSA-N 4-methylcyclohexan-1-ol Chemical compound CC1CCC(O)CC1 MQWCXKGKQLNYQG-UHFFFAOYSA-N 0.000 claims 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
125000000753 cycloalkyl group Chemical group 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
150000001450 anions Chemical class 0.000 description 5
125000003118 aryl group Chemical group 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
229910052801 chlorine Inorganic materials 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000002904 solvent Substances 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
229910052794 bromium Inorganic materials 0.000 description 4
150000001768 cations Chemical class 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
239000000243 solution Substances 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
125000001072 heteroaryl group Chemical group 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
239000011975 tartaric acid Substances 0.000 description 3
235000002906 tartaric acid Nutrition 0.000 description 3
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
235000011054 acetic acid Nutrition 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 2
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000006264 debenzylation reaction Methods 0.000 description 2
SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
235000011389 fruit/vegetable juice Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
150000003840 hydrochlorides Chemical class 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
150000002900 organolithium compounds Chemical class 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
229960003975 potassium Drugs 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
CIWXOQMJYOKEKW-UHFFFAOYSA-N 1-(3-cyclopentyloxyphenyl)-2-[(dimethylamino)methyl]-6-methylcyclohexan-1-ol Chemical compound CC1CCCC(CN(C)C)C1(O)C1=CC=CC(OC2CCCC2)=C1 CIWXOQMJYOKEKW-UHFFFAOYSA-N 0.000 description 1
PLDWAJLZAAHOGG-UHFFFAOYSA-N 1-bromo-3-methoxybenzene Chemical compound COC1=CC=CC(Br)=C1 PLDWAJLZAAHOGG-UHFFFAOYSA-N 0.000 description 1
FFFIRKXTFQCCKJ-UHFFFAOYSA-N 2,4,6-trimethylbenzoic acid Chemical compound CC1=CC(C)=C(C(O)=O)C(C)=C1 FFFIRKXTFQCCKJ-UHFFFAOYSA-N 0.000 description 1
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
XCDOFNWFSLYMBR-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-[3-(2-methoxyethoxy)phenyl]-6-methylcyclohexan-1-ol Chemical compound COCCOC1=CC=CC(C2(O)C(CCCC2C)CN(C)C)=C1 XCDOFNWFSLYMBR-UHFFFAOYSA-N 0.000 description 1
QDRGQWHTKFHCJT-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-6-methyl-1-(3-phenylmethoxyphenyl)cyclohexan-1-ol Chemical compound CC1CCCC(CN(C)C)C1(O)C1=CC=CC(OCC=2C=CC=CC=2)=C1 QDRGQWHTKFHCJT-UHFFFAOYSA-N 0.000 description 1
LFSAPCRASZRSKS-UHFFFAOYSA-N 2-methylcyclohexan-1-one Chemical compound CC1CCCCC1=O LFSAPCRASZRSKS-UHFFFAOYSA-N 0.000 description 1
VIKBNMWOLLIQPG-UHFFFAOYSA-N 2-methyldecanedioic acid Chemical compound OC(=O)C(C)CCCCCCCC(O)=O VIKBNMWOLLIQPG-UHFFFAOYSA-N 0.000 description 1
AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
RREANTFLPGEWEN-MBLPBCRHSA-N 7-[4-[[(3z)-3-[4-amino-5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidin-2-yl]imino-5-fluoro-2-oxoindol-1-yl]methyl]piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(\N=C/3C4=CC(F)=CC=C4N(CN4CCN(CC4)C=4C(=CC=5C(=O)C(C(O)=O)=CN(C=5C=4)C4CC4)F)C\3=O)=NC=2)N)=C1 RREANTFLPGEWEN-MBLPBCRHSA-N 0.000 description 1
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
206010038678 Respiratory depression Diseases 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
240000000581 Triticum monococcum Species 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
238000005902 aminomethylation reaction Methods 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
150000005840 aryl radicals Chemical class 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
239000012964 benzotriazole Substances 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
150000001767 cationic compounds Chemical class 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000012069 chiral reagent Substances 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
238000005661 deetherification reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
CSOJGJKUVVYZJE-UHFFFAOYSA-N dichloromethane;n-methylmethanamine Chemical compound CNC.ClCCl CSOJGJKUVVYZJE-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
125000003914 fluoranthenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC=C4C1=C23)* 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
150000002366 halogen compounds Chemical class 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910001411 inorganic cation Inorganic materials 0.000 description 1
230000003993 interaction Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 description 1
239000011505 plaster Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
235000011181 potassium carbonates Nutrition 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000036280 sedation Effects 0.000 description 1
230000020341 sensory perception of pain Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Psychology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Surgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

ZA200303214A 2000-09-29 2003-04-24 O-substituated 6-methyl-tramadol derivatives. ZA200303214B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10049483A DE10049483A1 (de)	2000-09-29	2000-09-29	Substituierte 1-Aminobutan-3-ol-Derivate

Publications (1)

Publication Number	Publication Date
ZA200303214B true ZA200303214B (en)	2004-08-31

Family

ID=7658871

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ZA200303220A ZA200303220B (en)	2000-09-29	2003-04-24	Substituted 1-aminobutan-3-ol-derivatives.
ZA200303214A ZA200303214B (en)	2000-09-29	2003-04-24	O-substituated 6-methyl-tramadol derivatives.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
ZA200303220A ZA200303220B (en)	2000-09-29	2003-04-24	Substituted 1-aminobutan-3-ol-derivatives.

Country Status (29)

Country	Link
US (2)	US7022739B2 (ru)
EP (2)	EP1322592B2 (ru)
JP (2)	JP2004509939A (ru)
KR (2)	KR100835549B1 (ru)
CN (2)	CN1478067A (ru)
AR (1)	AR034158A1 (ru)
AT (2)	ATE272045T1 (ru)
AU (4)	AU2001289937B2 (ru)
BR (2)	BR0114381A (ru)
CA (2)	CA2423860A1 (ru)
DE (3)	DE10049483A1 (ru)
DK (2)	DK1322592T4 (ru)
EC (2)	ECSP034532A (ru)
ES (2)	ES2225628T3 (ru)
HK (2)	HK1052924B (ru)
HU (2)	HUP0303195A3 (ru)
IL (2)	IL155105A0 (ru)
MX (2)	MXPA03002737A (ru)
NO (2)	NO20031382L (ru)
NZ (2)	NZ524976A (ru)
PE (1)	PE20020413A1 (ru)
PL (2)	PL361382A1 (ru)
PT (2)	PT1322593E (ru)
RU (2)	RU2288219C2 (ru)
SI (2)	SI1322593T1 (ru)
SK (2)	SK286727B6 (ru)
TR (2)	TR200402230T4 (ru)
WO (2)	WO2002026694A1 (ru)
ZA (2)	ZA200303220B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10049483A1 (de) *	2000-09-29	2002-05-02	Gruenenthal Gmbh	Substituierte 1-Aminobutan-3-ol-Derivate
CN1599607A (zh)	2001-10-16	2005-03-23	恩都制药公司	用于治疗神经机能障碍的甲醇
DK1471054T3 (da) *	2002-01-11	2009-11-09	Daiichi Sankyo Co Ltd	Aminoalkohol-derivat eller phosphonsyre-derivat og medicinsk sammensætning, der indeholder disse
US20050182056A9 (en) *	2002-02-21	2005-08-18	Seth Pawan	Modified release formulations of at least one form of tramadol
US8128957B1 (en)	2002-02-21	2012-03-06	Valeant International (Barbados) Srl	Modified release compositions of at least one form of tramadol
ATE465726T1 (de)	2002-11-22	2010-05-15	Gruenenthal Gmbh	Verwendung von (1r, 2r)-3-(3-dimenthylamino-1- ethyl-2-methyl-propyl)-phenol zur behandlung von entzündungsschmerz
KR20110136901A (ko)	2004-02-24	2011-12-21	상꾜 가부시키가이샤	아미노 알코올 화합물
KR101581289B1 (ko) *	2007-05-31	2015-12-31	세프라코 아이엔시.	모노아민 재흡수 억제제로서 페닐 치환된 시클로알킬아민
CA2744713A1 (en) *	2008-12-05	2010-06-10	Arqule, Inc.	Raf inhibitors and their uses
ES2343050B1 (es) *	2008-12-16	2011-06-14	Chemo Iberica, S.A.	Procedimiento para la preparacion de desvenlafaxina y sus sales de adicion de acido farmaceuticamente aceptables.
WO2012100423A1 (en) *	2011-01-27	2012-08-02	Eli Lilly And Company	Analgesic compounds, methods, and formulations
JP2019502761A (ja) *	2016-01-21	2019-01-31	ラボラトリオスレヴィエセエレ	（（ｒ）−３−［（−１−メチルピロリジン−２−イル）メチル］−５−（２−フェニルスルホニルエチル）−１ｈ−インドールを作製する方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3652589A (en) *	1967-07-27	1972-03-28	Gruenenthal Chemie	1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
ZA732238B (en) *	1972-04-06	1974-01-30	American Home Prod	Benzylamine analgesics
US4155935A (en) *	1973-03-26	1979-05-22	American Home Products Corporation	Benzylamine analgesics
DE19525137C2 (de) *	1995-07-11	2003-02-27	Gruenenthal Gmbh	6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe
US6017963A (en) *	1995-11-14	2000-01-25	Euro-Celtique, S.A.	Formulation for intranasal administration
DE19547766A1 (de)	1995-12-20	1997-06-26	Gruenenthal Gmbh	1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-verbindungen als pharmazeutische Wirkstoffe
DE19601744C2 (de)	1996-01-19	1998-04-16	Gruenenthal Gmbh	Verfahren zur Herstellung der Enantiomeren von O-Demethyltramadol
DE19609847A1 (de) †	1996-03-13	1997-09-18	Gruenenthal Gmbh	Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe
US5919826A (en) *	1996-10-24	1999-07-06	Algos Pharmaceutical Corporation	Method of alleviating pain
US6245804B1 (en) *	1997-05-30	2001-06-12	Schering Aktiengesellschaft	Nonsteroidal gestagens
CA2295884A1 (en) *	1997-07-15	1999-01-28	Russinsky Limited	Tramadol, salts thereof and process for their preparation
ES2212849T3 (es) *	1998-05-22	2004-08-01	Mallinckrodt Inc.	Sintesis y purificacion mejoradas de hidrocloruro de (r,r)-2-((dimetilamino)metil)-1-(3-metoxifenil)ciclohexanol.
ES2141688B1 (es) *	1998-11-06	2001-02-01	Vita Invest Sa	Nuevos esteres derivados de compuestos fenil-ciclohexil sustituidos.
DE19915601A1 (de) *	1999-04-07	2000-10-19	Gruenenthal Gmbh	3-Amino-3-arylpropan-1-ol-Derivate, deren Herstellung und Verwendung
US6562865B1 (en) *	1999-08-20	2003-05-13	Ortho-Mcneil Pharmaceutical, Inc.	Composition comprising a tramadol material and an anticonvulsant drug
PE20010623A1 (es) *	1999-10-05	2001-07-07	Gruenenthal Chemie	Uso de (+)-tramadol y/o o-demetiltramadol para tratamiento de urgencia urinaria incrementada y/o incontinencia urinaria
US6339105B1 (en) *	1999-10-12	2002-01-15	Ortho-Mcneil Pharmaceutical, Inc.	Analgesic regimen
DE10000312A1 (de) *	2000-01-05	2001-07-12	Gruenenthal Gmbh	Substituierte Aminomethyl-Phenyl-Cyclohexanderivate
DE10049483A1 (de) *	2000-09-29	2002-05-02	Gruenenthal Gmbh	Substituierte 1-Aminobutan-3-ol-Derivate
DE10048714A1 (de) *	2000-09-30	2002-04-11	Gruenenthal Gmbh	5-Amino-1-penlen-3-ol-Derivate
US6649783B2 (en) *	2001-10-03	2003-11-18	Euro-Celtique, S.A.	Synthesis of (+/-)-2-((dimethylamino)methyl)-1-(aryl)cyclohexanols
AU2002364517A1 (en) *	2001-11-30	2003-06-17	Sepracor Inc.	Tramadol analogs and uses thereof

2000
- 2000-09-29 DE DE10049483A patent/DE10049483A1/de not_active Withdrawn
2001
- 2001-09-28 DK DK01969791T patent/DK1322592T4/da active
- 2001-09-28 KR KR1020037004490A patent/KR100835549B1/ko not_active IP Right Cessation
- 2001-09-28 AR ARP010104583A patent/AR034158A1/es unknown
- 2001-09-28 PT PT01985699T patent/PT1322593E/pt unknown
- 2001-09-28 RU RU2003111753/04A patent/RU2288219C2/ru not_active IP Right Cessation
- 2001-09-28 BR BR0114381-6A patent/BR0114381A/pt not_active IP Right Cessation
- 2001-09-28 AU AU2001289937A patent/AU2001289937B2/en not_active Ceased
- 2001-09-28 PE PE2001000968A patent/PE20020413A1/es not_active Application Discontinuation
- 2001-09-28 IL IL15510501A patent/IL155105A0/xx unknown
- 2001-09-28 JP JP2002531080A patent/JP2004509939A/ja active Pending
- 2001-09-28 JP JP2002532404A patent/JP2004510755A/ja active Pending
- 2001-09-28 EP EP01969791A patent/EP1322592B2/de not_active Expired - Lifetime
- 2001-09-28 AU AU2002220578A patent/AU2002220578B2/en not_active Ceased
- 2001-09-28 SK SK340-2003A patent/SK286727B6/sk not_active IP Right Cessation
- 2001-09-28 HU HU0303195A patent/HUP0303195A3/hu unknown
- 2001-09-28 NZ NZ524976A patent/NZ524976A/en unknown
- 2001-09-28 ES ES01985699T patent/ES2225628T3/es not_active Expired - Lifetime
- 2001-09-28 ES ES01969791T patent/ES2225605T5/es not_active Expired - Lifetime
- 2001-09-28 CA CA002423860A patent/CA2423860A1/en not_active Abandoned
- 2001-09-28 MX MXPA03002737A patent/MXPA03002737A/es active IP Right Grant
- 2001-09-28 IL IL15510601A patent/IL155106A0/xx unknown
- 2001-09-28 TR TR2004/02230T patent/TR200402230T4/xx unknown
- 2001-09-28 SI SI200130189T patent/SI1322593T1/xx unknown
- 2001-09-28 BR BR0114380-8A patent/BR0114380A/pt not_active IP Right Cessation
- 2001-09-28 KR KR1020037004521A patent/KR100864796B1/ko not_active IP Right Cessation
- 2001-09-28 AT AT01969791T patent/ATE272045T1/de active
- 2001-09-28 HU HU0303361A patent/HUP0303361A3/hu unknown
- 2001-09-28 AU AU8993701A patent/AU8993701A/xx active Pending
- 2001-09-28 DK DK01985699T patent/DK1322593T3/da active
- 2001-09-28 SI SI200130184T patent/SI1322592T1/xx unknown
- 2001-09-28 CN CNA018196454A patent/CN1478067A/zh active Pending
- 2001-09-28 CA CA002423903A patent/CA2423903A1/en not_active Abandoned
- 2001-09-28 RU RU2003111756/04A patent/RU2286334C2/ru not_active IP Right Cessation
- 2001-09-28 CN CNB018166067A patent/CN100391933C/zh not_active Expired - Fee Related
- 2001-09-28 WO PCT/EP2001/011276 patent/WO2002026694A1/de active IP Right Grant
- 2001-09-28 EP EP01985699A patent/EP1322593B1/de not_active Expired - Lifetime
- 2001-09-28 AU AU2057802A patent/AU2057802A/xx active Pending
- 2001-09-28 PT PT01969791T patent/PT1322592E/pt unknown
- 2001-09-28 TR TR2004/02030T patent/TR200402030T4/xx unknown
- 2001-09-28 PL PL01361382A patent/PL361382A1/xx unknown
- 2001-09-28 WO PCT/EP2001/011231 patent/WO2002028817A1/de active IP Right Grant
- 2001-09-28 MX MXPA03002738A patent/MXPA03002738A/es active IP Right Grant
- 2001-09-28 DE DE50103036T patent/DE50103036D1/de not_active Expired - Lifetime
- 2001-09-28 SK SK338-2003A patent/SK3382003A3/sk not_active Application Discontinuation
- 2001-09-28 NZ NZ525171A patent/NZ525171A/en unknown
- 2001-09-28 PL PL01361632A patent/PL361632A1/xx not_active Application Discontinuation
- 2001-09-28 DE DE50103035T patent/DE50103035D1/de not_active Expired - Lifetime
- 2001-09-28 AT AT01985699T patent/ATE272046T1/de not_active IP Right Cessation
2003
- 2003-03-26 NO NO20031382A patent/NO20031382L/no not_active Application Discontinuation
- 2003-03-26 NO NO20031387A patent/NO20031387L/no not_active Application Discontinuation
- 2003-03-28 EC EC2003004532A patent/ECSP034532A/es unknown
- 2003-03-28 EC EC2003004530A patent/ECSP034530A/es unknown
- 2003-03-28 US US10/401,020 patent/US7022739B2/en not_active Expired - Fee Related
- 2003-03-31 US US10/402,147 patent/US6828345B2/en not_active Expired - Fee Related
- 2003-04-24 ZA ZA200303220A patent/ZA200303220B/en unknown
- 2003-04-24 ZA ZA200303214A patent/ZA200303214B/en unknown
- 2003-07-16 HK HK03105140.5A patent/HK1052924B/zh not_active IP Right Cessation
- 2003-07-17 HK HK03105163.7A patent/HK1052925B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
PT1322592E (pt)	2004-12-31
KR100835549B1 (ko)	2008-06-09
EP1322592B1 (de)	2004-07-28
TR200402030T4 (tr)	2004-09-21
IL155105A0 (en)	2003-10-31
HK1052924A1 (en)	2003-10-03
EP1322593A1 (de)	2003-07-02
CA2423860A1 (en)	2003-03-27
AU2057802A (en)	2002-04-08
ES2225605T5 (es)	2009-11-18
HUP0303361A3 (en)	2007-03-28
NZ524976A (en)	2005-01-28
SI1322592T1 (en)	2005-02-28
HK1052924B (zh)	2005-03-24
MXPA03002737A (es)	2004-01-26
PL361382A1 (en)	2004-10-04
AR034158A1 (es)	2004-02-04
NZ525171A (en)	2006-02-24
JP2004509939A (ja)	2004-04-02
US7022739B2 (en)	2006-04-04
ES2225628T3 (es)	2005-03-16
NO20031387L (no)	2003-05-21
KR20030077531A (ko)	2003-10-01
HUP0303195A2 (hu)	2003-12-29
IL155106A0 (en)	2003-10-31
DE50103036D1 (de)	2004-09-02
CN1478067A (zh)	2004-02-25
TR200402230T4 (tr)	2004-10-21
HK1052925B (zh)	2005-04-01
MXPA03002738A (es)	2004-01-26
KR20030059160A (ko)	2003-07-07
HUP0303195A3 (en)	2007-03-28
SK3402003A3 (en)	2003-09-11
ES2225605T3 (es)	2005-03-16
WO2002028817A1 (de)	2002-04-11
ATE272046T1 (de)	2004-08-15
US20030220389A1 (en)	2003-11-27
RU2288219C2 (ru)	2006-11-27
RU2286334C2 (ru)	2006-10-27
KR100864796B1 (ko)	2008-10-23
DK1322593T3 (da)	2004-10-11
PL361632A1 (en)	2004-10-04
NO20031382D0 (no)	2003-03-26
PE20020413A1 (es)	2002-05-18
AU2001289937B2 (en)	2007-01-18
SK3382003A3 (en)	2003-08-05
BR0114380A (pt)	2003-12-30
ECSP034530A (es)	2003-05-26
ECSP034532A (es)	2003-05-26
EP1322592A1 (de)	2003-07-02
ZA200303220B (en)	2004-08-19
HUP0303361A2 (hu)	2004-03-01
NO20031387D0 (no)	2003-03-26
NO20031382L (no)	2003-05-16
WO2002026694A1 (de)	2002-04-04
DK1322592T3 (da)	2004-11-22
ATE272045T1 (de)	2004-08-15
AU8993701A (en)	2002-04-15
SK286727B6 (sk)	2009-04-06
DE50103035D1 (de)	2004-09-02
CN100391933C (zh)	2008-06-04
CA2423903A1 (en)	2003-03-27
AU2002220578B2 (en)	2006-11-30
US20030216393A1 (en)	2003-11-20
SI1322593T1 (en)	2004-12-31
US6828345B2 (en)	2004-12-07
DE10049483A1 (de)	2002-05-02
EP1322593B1 (de)	2004-07-28
HK1052925A1 (en)	2003-10-03
BR0114381A (pt)	2003-12-30
PT1322593E (pt)	2004-12-31
JP2004510755A (ja)	2004-04-08
DK1322592T4 (da)	2009-10-12
CN1466567A (zh)	2004-01-07
EP1322592B2 (de)	2009-06-17

Publication	Publication Date	Title
RU2178409C2 (ru)	2002-01-20	6-диметиламинометил-1-фенилциклогексановые соединения в качестве фармацевтически действующих веществ и способы их получения (варианты)
JP4848268B2 (ja)	2011-12-28	置換された３−アリールブチル−アミン−化合物の製造方法
US7276518B2 (en)	2007-10-02	Substituted cyclohexane-1,4-diamine compounds
CA2352324C (en)	2011-11-22	Derivatives of (-)-venlafaxine and methods of preparing and using the same
ZA200303214B (en)	2004-08-31	O-substituated 6-methyl-tramadol derivatives.
PL187373B1 (pl)	2004-06-30	Sposób wytwarzania enancjomerów 3-(2-dimetyloaminometylo-1-hydroksycykloheksylo) fenolu
NZ525170A (en)	2006-08-31	Substituted C-cyclohexylmethylamine derivatives
US7595340B2 (en)	2009-09-29	Serotonin and norepinephrine reuptake inhibitor and uses thereof
JP4126271B2 (ja)	2008-07-30	置換された４−アミノシクロヘキサノール誘導体
US6815443B2 (en)	2004-11-09	5-Amino-1-pentene-3-ol substituted derivatives
US20070015791A1 (en)	2007-01-18	Serotonin and norepinephrine reuptake inhibitors and uses thereof
IL135452A (en)	2004-02-08	3-amino-3-arylpropan-1-ol derivatives, their preparation and medicaments comprising them
US20050096361A1 (en)	2005-05-05	Beta-amino ketones for the treatment of pain
DE10206404A1 (de)	2003-08-28	Synthese von substituierten Sulfonylaminen